On 26 March 2024, MSD announced that its WINREVAIR™ (sotatercept-csrk) has been approved by the FDA for treating...
Sam Chun Dang to Distribute Eylea® (aflibercept) Biosimilar in Nine European Countries
The Korea Biomedical Review reports that South Korean company, Sam Chun Dang Pharm Co Ltd (SCD), has entered an...
Novo Nordisk to Acquire Cardior in €1.025B Acquisition
On 25 Mar 2024, Novo Nordisk announced the acquisition of Cardior Pharmaceuticals for (up to) € 1.025B comprised of an...
Samsung Bioepis Initiates Novel Drug Development for Rare Diseases
On 24 March 2024, the Korea Economic Daily (KED) reported Samsung Bioepis entered pre-clinical stage, with multiple...
Samsung Bioepis Seeks to Revoke Janssen’s Stelara® (ustekinumab) Patents in Australian Court
On 22 March 2024, the first case management hearing was held before Justice Nicholas in the Federal Court of...
Novo Nordisk’s Awiqli® (insulin) Recommended for EU Approval
On 22 March 2024 Novo Nordisk announced that it has received a positive opinion from the European Medicines Agency’s...
CHMP Positive Opinion for Sandoz’s Denosumab and Celltrion’s Omalizumab Biosimilars
On 22 March 2024, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency published...
Samsung Bioepis Enters Collaboration Agreement with Geo-Young For Biosimilar Distribution
On 22 March 2024, Korea Biomedical Review reported Geo-Young, South Korea's largest pharmaceutical distributor,...
New Indication Alert: BMS’s Abecma® (idecabtagene vicleucel) Receives EU Approval For Extended Indication
On 20 March, 2024, BMS announced that its CAR-T cell immunotherapy Abecma ® (idecabtagene vicleucel) was granted an...
Alvotech Reports Full Year Financial Results and Provides a Business Update
On 20 March 2024, Alvotech announced its full year financial results for 2023, highlighting increased product revenue...
Novo Nordisk Announces USD 560 Million Investment in its Chinese Facility
On 20 March 2024, China Daily reported that Novo Nordisk has announced investing USD 560 million in its Chinese...
Lonza Buys Vacaville (US) Biologics Site from Roche for $1.2 Billion to Increase Lonza’s Commercial Manufacturing Capabilities
On 20 March 2024, Lonza announced it has entered an agreement to acquire Genentech’s large-scale biologics...
Dr Reddy Launches its First UK Biosimilar (bevacizumab) 5 Years After Indian Launch and 6 Years After First Bevacizumab UK Biosimilar Approval
On 19 March 2024, Dr. Reddy's announced the launch of its Versavo® (bevacizumab) in the UK. Versavo® is a biosimilar...
Fresenius & Formycon Settle with J&J in Europe and Canada over Ustekinumab Biosimilar
On 18 March 2024 Fresenius Kabi and Formycon announced they reached a settlement with Johnson & Johnson regarding...
Bio-Thera Solutions Partners with SteinCares to Market Two Biosimilars in LATAM
On 18 March 2024, Bio-Thera Solutions announced that it is partnering with SteinCares to commercialise two unnamed...
Celltrion’s Sub-cutaneous Zymfentra™ (infliximab-dyyb) US Launched
On 17 March 2024, Celltrion USA launched ZYMFENTRA™ (infliximab-dyyb), the first subcutaneous formulation of...